Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$27.06 1.30 (5.05%)
2/9/2010 4:00 PM

Human Genome Sciences (HGSI)

CAPS Rating:
*

The drug development company with three products advancing into late-stage clinical development: Albuferon(r) for chronic hepatitis C, LymphoStat-B(r) for systemic lupus erythematosus, and ABthraxtm for anthrax disease.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating HGSI

Add Stock to Watchlist

What the Community Thinks

Total Members

429 Outperforms
193 Underperforms
 

All-Stars

146 Outperforms
80 Underperforms
 

Wall Street

17 Outperforms
0 Underperforms
 

Members bullish on HGSI are also bullish on:

Members bearish on HGSI are also bearish on:

Ticker Tags

Growth (1902), Biotechnology (220), Healthcare (711), Distressed (1597), Aggressive Growth (860), Mid Cap (610), Defensive (1457), Genomics (14), Rule Breakers Universe (125)
Suggest a tag

Human Genome Sciences At A Glance

Current Price: $27.06
Last Trade Time: 2/9/2010 4:00 PM
Open: $26.12
Previous Close: $25.76
Daily Range: $26.06 - $27.19
52-Week Range: $0.45 - $32.07
Volume: 4,094,622
Market Cap: $4.47B
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

HGSI VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

9

Human Genome Sciences (HGSI)

Avatar usubanas (99.58) Submitted: 8/04/09 11:53 PM

I owe this one a pitch since it's my best performer and probably will be for a while...

I'll give you a basic analysis. The lupus market that this drug would cover ranges from $1 to $4 billion, according to analyst estimates. HGSI gets 50% of sales, the other 50% goes to their partner GlaxoSmithKl...More

Replies: 2 | Reply | Permalink

Top Bear Pitch

Recs

19

Human Genome Sciences (HGSI)

Avatar UltraLong (100.00) Submitted: 7/21/09 2:43 PM

You know the apocalypse is near when Human Genome Sciences is outperforming the market. This company was written off for dead back in March after yet another failed drug study.

So let's analyze what we have here. They finally, after countless tried, found a drug that works better at controlling th...More

Replies: 13 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 91 :   1 2 3 4 5 Next » Jump to page:

Show Pitch Replies

Recs

0

 (HGSI)

Avatar DavidSobel (38.25) Submitted: 2/02/10 6:50 PM : Outperform Start Price: $27.55 HGSI Score: -0.16

this is a winner

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (HGSI)

Avatar CaptainFiveBaggr (99.65) Submitted: 1/06/10 3:44 PM : Underperform Start Price: $31.31 HGSI Score: 7.90

About time to ride this train back down to reality.... Sorry its just that percentages in the thousands tend to level off before they continue to rise...

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (HGSI)

Avatar Redhat821 (< 20) Submitted: 12/13/09 2:05 PM : Outperform Start Price: $28.08 HGSI Score: 0.52

Not investing in HGSI is like throwing money into the trash. And shorting this stock is like stepping in front of a freight train... Ouch and bankruptcy rolled into one.

Why HGSI will be the next large cap biotech company if it's not bought out:

1. Benlysta (HGSI) for Lupus is significantly underappreciated. 5M WW suffer from Lupus. Last approved therapy was in the 1960s - steroids (nasty side effects and not very effective). Benlysta will have market exclusivity for quite sometime (nothing in the near term in pipelines for other companies). Pricing for Benlysta is estimated to be around $30K. You can do the math on the market potential.

2. Benlysta works in other autoimmune diseases - MS and RA to name a few. Any additional indication would be gravy, since you can leverage the same sales force (same doctors targeted).

3. Albuferon for HEP C for free.

4. Cancer pipeline for free.

5. Almost every large pharma/biotech company is calling HGSI to find out their price for a takeout. Large pharma.biotech companies are suffering from depleted pipelines, facing a huge patent cliff on their current existing drugs/biologics, and have lots of cash on hand. HGSI is a no brainer.

Report this Post Replies: 2 | Reply | Permalink

Recs

0

 (HGSI)

Avatar lonewulf47638 (63.75) Submitted: 12/08/09 7:29 AM : Outperform Start Price: $27.29 HGSI Score: 1.72

funding now available.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (HGSI)

Avatar mistercube (86.25) Submitted: 12/03/09 11:17 AM : Underperform Start Price: $29.00 HGSI Score: 2.92

Let me get this straight. The company offers umpteen million dilutive shares (~10%) for sale below market price and buyers flock in to bump HGSI upwards to the tune of 6% before noon?

I'll short this one for a few months, thank you.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 91 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 17 of 17  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackJimCramer < 20 11/04/09 Outperform 3W $26.48+2.19%+2.19% 0
TrackJPMorgan 84.76 10/30/09 Outperform NS $19.26+40.50%+1.93%+38.57
TrackPiperJaff 85.79 09/15/09 Outperform NS $19.00+42.42%+3.71%+38.71
TrackUBS 87.99 09/05/09 Outperform NS $18.86+43.48%+6.82%+36.66
TrackThinkEquity 64.82 07/21/09 Outperform NS $12.38+118.58%+12.37%+106.21
TrackCitigroup 85.92 07/20/09 Outperform NS $10.89+148.48%+13.78%+134.70
TrackStanfordRes 85.54 12/10/08 Outperform NS $1.94+1294.85%+21.94%+1272.90
TrackDeutscheSec 89.68 01/24/08 Outperform NS $6.20+336.21%-17.49%+353.69
TrackBearStearns 84.85 01/24/08 Outperform NS $6.10+343.61%-16.91%+360.52
TrackJMP 71.98 01/23/08 Outperform NS $5.64+379.79%-15.94%+395.72
TrackLeerinkSwan 92.83 01/02/08 Outperform NS $10.79+150.79%-23.58%+174.36
TrackEdwardOwens 98.91 09/30/07 Outperform NS $10.29+162.97%-26.38%+189.35 Toggle the visibility of 60-Second Pitch and replies
TrackSchneider < 20 09/30/07 Outperform NS $10.29+162.97%-26.38%+189.35 Toggle the visibility of 60-Second Pitch and replies
TrackBernstein 87.54 09/18/07 Outperform NS $9.75+177.54%-24.39%+201.92
TrackStifel 96.44 01/31/07 Outperform NS $11.81+129.13%-20.21%+149.34
TrackAGEdwards 93.04 01/04/07 Outperform NS $12.48+116.83%-19.42%+136.25
TrackTWeisel < 20 10/11/06 Outperform NS $12.88+110.09%-15.60%+125.69

Results 1 - 17 of 17  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD04 859ms